Pfizer Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PFE research report →
About the company
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis.
- CEO
- Albert Bourla
- IPO
- 1972
- Employees
- 75,000
- HQ
- New York City, NY, US
Price Chart
Get TickerSpark's AI analysis on PFE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $142.77B
- P/E
- 19.12
- P/S
- 2.25
- P/B
- 1.58
- EV/EBITDA
- 12.27
- Div Yield
- 6.87%
- Gross Margin
- 69.35%
- Op Margin
- 23.45%
- Net Margin
- 11.83%
- ROE
- 8.37%
- ROIC
- 7.97%
- Revenue
- $62.58B · -1.65%
- Net Income
- $7.77B · -3.12%
- EPS
- $1.36 · -4.23%
- Op Income
- $15.44B
- FCF YoY
- -7.72%
- 52W High
- $28.75
- 52W Low
- $23.11
- 50D MA
- $25.27
- 200D MA
- $25.89
- Beta
- 0.31
- Avg Volume
- 41.43M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 15, 26 | BOURLA ALBERT | other | 24 |
| Jul 9, 26 | BOURLA ALBERT | other | 84 |
| Jun 30, 26 | BOURLA ALBERT | other | 25 |
| Jun 26, 26 | Buckley Mortimer J | other | 1,543.845 |
| Jun 26, 26 | Echevarria Joseph | other | 1,904.076 |
| Jun 26, 26 | NARAYEN SHANTANU | other | 2,058.46 |
| Jun 26, 26 | SMITH JAMES C | other | 1,852.614 |
| Jun 26, 26 | Quincey James | other | 1,595.307 |
| Jun 26, 26 | Taraporevala Cyrus | other | 1,543.845 |
| Jun 15, 26 | BOURLA ALBERT | other | 23 |
Our PFE coverage
Recent articles, reports, and earnings notes.
The GLP-1 trade is becoming a market-share war, not a rising-tide story
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
Merck’s latest data may have bought it more time than bears want to admit
Merck’s patent-cliff problem is real, but the market is acting like the runway ends tomorrow when the core franchise is still expanding today. Fresh lung-cancer data, rising Keytruda sales, and a packed oncology catalyst calendar make MRK look stronger than the fear trade suggests.
Want a deeper read on PFE?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.